Pear Therapeutics, Inc.

News Release

Pear Therapeutics to Present at 38th Annual Cowen Health Care Conference

March 6, 2018

Boston, March 6, 2018 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Cowen Health Care Conference on Tuesday, March 13, 2018, at 12:30 p.m. ET at the Boston Marriott Copley Place in Boston.

Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-cleared software applications to treat serious medical conditions.

About Pear Therapeutics

Pear Therapeutics is the leader in FDA-cleared prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapeutic for Substance Use Disorder to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O™ for opioid use disorder and additional prescription digital therapeutics in schizophrenia (THRIVE™), combat posttraumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia, for which Pear intends to obtain FDA clearance. For more details, please see

Media contacts:
Karen Sharma or Stefanie Tuck
MacDougall Biomedical Communications